1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > 2016 Emerging Strategies for the US Hospital Tumor Marker Testing Market

2016 Emerging Strategies for the US Hospital Tumor Marker Testing Market

  • October 2015
  • -
  • Venture Planning Group
  • -
  • 567 pages

This new report from VPGMarketResearch.com contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital tumor market testing market, including: 

  • Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. 
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. 
  • Test volume and sales forecasts for 40 tumor markers performed in US hospitals. 
  • Current instrumentation technologies and feature comparison of leading analyzers. 
  • Sales and market shares of leading suppliers. 
  • Emerging diagnostic technologies and their potential market applications. 
  • Product development opportunities. 
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. 
  • Business opportunities and strategic recommendations for suppliers. 

            Contains 567 pages and 50 tables

This new report from VPGMarketResearch.com contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital tumor market testing market, including:

Table Of Contents

2016 Emerging Strategies for the US Hospital Tumor Marker Testing Market
Introduction
Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Brest Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin

16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
- ADA
- B-Protein
- PNP
- 5'-Nucleotidase
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src


28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3

- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1

- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opiod Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Instrumentation Review
And Market Needs
1. Abbott AxSYM
2. Abbott Architect c4000
3. Abbott Architect i2000 Series
4. Abbott Architect ci8200 System

5. Beckman Coulter UniCel Series
6. Beckman Coulter Access
7. Binding Site ESP600
8. bioMerieux Mini Vidas
9. Carolina Chemistries BioLis 24i
10. DiaSorin Liaison
11. Horiba ABX Pentra 400
12. Inverness DS2
13. JandJ Vitros ECi/ECiQ
14. JandJ Vitros 3600
15. JandJ Vitros 5600
16. Olympus AU5400
17. Olympus AU3000i
18. Olympus AU2700
19. Roche Modular Analytics
20. Roche Cobas Integra 400
21. Roche Cobas Integra 400 Plus
22. Roche Elecsys
23. Roche Cobas c311
24. Siemens ADVIA Centaur
25. Siemens Dimension
26. Siemens Dimension RxL Max
27. Siemens Dimension Vista 500
28. Siemens Immulite
29. Siemens Stratus
30. Tosoh AIA-Series
31. Vital Diagnostics ATAC 8000
32. Vital Diagnostics Envoy 500
D. Current and Emerging Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Immunofiltration
- Particle-Membrane Capture Immunoassay
- Enzyme Amplification

d. Fluorescent Immunoassays
e. Luminescence
- Chemiluminescence
- Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
H. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
3. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
- PCR
- DAP-PCR
- Immuno-PCR
- QC-PCR
- CAR
- DNA
- HPA
- LCR
- NASBA
- QBR
- SDA
- 3 SR, and others
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas
Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI

c. NMR
d. PET
e. Photonics Spectroscopy
E. Personal Testing
U.S.A.
A. Executive Summary
B. Business Environment
1. Health Care Expenditures
2. Cost Consciousness
3. Industry Consolidation
4. Managed Care
5. Hospitals
6. Admissions
7. Length of Stay
8. Industry Diversification
9. Physician Demographics
10. Population Aging
a. Chronic Illness
b. Disease Incidence
c. Susceptibility to Iatrogenesis
d. Multiple Illness Cases
11. Laboratory Regulations
C. Market Structure
1. Centralized Testing
a. Hospitals
b. Commercial/Private Laboratories
2. POT/Decentralized Testing
a. Physician Offices/Group Practices
b. Cancer Clinics
c. Point-Of-Care Testing
d. Other Decentralized Testing Locations
D. Market Size, Growth and Major Suppliers Sales,
Instrument Placements and Market Shares

Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
Design Criteria for Decentralized Testing Products
Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
Competitive Profiles
- Abbott
- AdnaGen
- Agilent Technologies
- Applied Gene Technologies

- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Elitech Group
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
- Otho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche

- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics and Therapeutics
- Thermo Fisher
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila/Alere


- Arca
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- Cepheid
- Correlogic Systems
- Dako
- Decode
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Gen-Probe
- Guided Therapeutics
- Hologic
- Ipsogen
- Kreatech
- Kyowa Medex
- Life Technologies
- Mackay Life Sciences
- Myriad Genetics
- Nanogen Elitech
- OncoLab
- Otho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Radient Pharmaceuticals
- Roche

- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics and Therapeutics
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila


List of Tables

Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests
List of Tables (continued)
Major Companies Developing or Marketing
HCG Tests

Major Companies Developing or Marketing
Insulin Tests

Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications
In Cancer Diagnosis
List of Tables (continued)
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis
Executive Summary Table: U.S., Hospital
Cancer Diagnostic Test Volume and Sales Forecast
U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates
Per 100,000 Population
U.S., Laboratories Performing Cancer Diagnostic
Tests
U.S., Hospital Laboratories Performing
Cancer Diagnostics Tests by Bed Size
U.S., Hospital Laboratories Major Cancer
Diagnostic Test Volume Forecast by Test
U.S., Total Cancer Diagnostics Sales
By Major Supplier
U.S., ACTH Testing Market Diagnostics
Sales by Major Supplier
U.S., AFP Testing Market Diagnostics
Sales by Major Supplier
U.S., Beta-2 Migroblolulin Testing Market
Diagnostics Sales by Major Supplier
U.S., CA 15-3/27.29 Testing Market
Diagnostics Sales by Major Supplier
U.S., CA 19-9 Testing Market Diagnostics
Sales by Major Supplier
U.S., CA 125 Testing Market Diagnostics
Sales by Major Supplier
List of Tables (continued)
U.S., CEA Testing Market Diagnostics
Sales by Major Supplier
U.S., Ferritin Testing Market
Diagnostics Sales by Major Supplier
U.S., HCG Testing Market
Diagnostics Sales by Major Supplier
U.S., Insulin Testing Market
Diagnostics Sales by Major Supplier
U.S., Parathyroid Hormone Testing
Market Diagnostics Sales by Major Supplier
U.S., PAP Testing Market Diagnostics
Sales by Major Supplier
U.S., Progesterone Receptor Testing Market
Diagnostics Sales by Major Supplier
U.S., PSA Testing Market Diagnostics
Sales by Major Supplier

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Breast Cancer Statistics in Africa

  • December 2016
    14 pages
  • Breast Cancer  

  • Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.